&w=3840&q=100)
E-commerce giant Flipkart offloads 6% stake in ABFRL; sells 73 mn shares
BS Reporter
Flipkart Investments on Wednesday offloaded 6 per cent stake in Aditya Birla Fashion & Retail Ltd (ABFRL) for ₹588 crore. The e-commerce giant sold 73.17 million shares at ₹80.32 apiece. Shares of ABFRL fell nearly 11 per cent in secondary market trading to end at ₹76.8.
Carlyle Group affiliate firm exits Indegene
Carlyle Group affiliate firm, C A Dawn Investments, on Wednesday sold its entire 10.20 per cent in Indegene for ₹1,447 crore. It sold nearly 24.5 million shares at ₹591 apiece. Shares of Indegene fell 4.7 per cent to end at ₹590.
Founder Kunhikannan sells 1.76% in Kaynes
Ramesh Kunhikannan, founder, Kaynes Technology on Wednesday divested his 1.76 per cent stake in the firm. He sold 11.25 million shares at ₹5,551 apeice to raise ₹623 crore. Shares of Kaynes fell about a per cent to close at ₹5,730 crore. BS reporters
Motilal Oswal Mutual Fund (MF) launched the first passive fund tracking the BSE 1000 index. The scheme Motilal Oswal BSE 1000 Index Fund, representing top 1000 listed companies offers exposure to about 94 per cent of the country's listed market capitalisation. The index at present has firms across 22 sectors. The top-10 stock weight is capped at 33 per cent to reduce concentration risk. Motilal Oswal is also in the process of finalising its plan to launch a scheme under the newly-introduced specialised investment fund (SIF) category in the next 6 months.
Sekhmet Pharma appoints Santosh Mahil MD & CEO
Private equity consortium led by PAG Sekhmet Pharmaventures has appointed Santosh Kumar Mahil (pictured) as the managing director (MD) and chief executive officer (CEO). Sekhmet is an investment platform that helps India's next generation of active pharmaceutical ingredient (API) companies. Mahil has nearly three decades of experience, having held leadership roles at Lupin, USV, Unichem, and Shilpa Medicare. BS reporter
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
a day ago
- Business Standard
Laxmi Dental share price rises 3%; Motilal Oswal initiates 'Buy'; check TP
Laxmi Dental share price rose 3.2 per cent in trade on Monday, logging an intraday high at ₹441.6 per share on BSE. At 9:27 AM, Laxmi Dental shares were trading higher by 2.2 per cent at ₹437.2 per share on the BSE. In comparison, the BSE Sensex was down 0.16 per cent at 82,369.42. The company's market capitalisation stood at ₹2,372.72 crore. The 52-week high of the stock was at ₹583.7 per share and the 52-week low of the stock was at ₹307.55 per share. Motilal Oswal initiates 'Buy' From the previous close at ₹427.8 per share, domestic brokerage Motilal Oswal sees a 26 per cent upside. The brokerage has initiated a 'Buy' and setting the target price at ₹540 per share. The brokerage cites supportive industry trends and the company's strong potential for sustained growth, assigning a 43x 12-month forward earnings multiple. Why is Motilal Oswal upbeat on Laxmi Dental? Over FY22–25, Laxmi Dental's revenue grew from ₹140 crore to ₹240 crore, while Earnings before interest, tax, depreciation and amortisation (Ebitda) margins expanded from 4 per cent to 17.5 per cent. Net profit for FY25 stood at ₹262 crore, recovering from a loss in FY22. Motilal Oswal projects a 24 per cent revenue compound annual growth rate (CAGR), 48 per cent Ebitda CAGR, and 62 per cent profit after tax (PAT) CAGR over FY25–27, driven by strong traction across its three core verticals—custom labs, clear aligners, and pediatric dental products. Track Stock Market LIVE Updates Segment-wise growth Lab business: The lab segment contributes 62 per cent of the company's total revenue. Motilal expects this vertical to grow at a 21 per cent CAGR through FY27, driven by rising adoption of digital dentistry, a shift towards premium metal-free crowns, and outsourcing by US-based dental labs to India. Clear aligners: Laxmi Dental is the only aligner company in India that is fully vertically integrated, having end-to-end capabilities from raw material to distribution. Further, the company's launch of clear aligners under the brand 'Illusion Aligners', was the first Indian brand to receive 510(k) clearance from the United States Food and Drugs Administration (US FDA) in CY21 to market clear aligners. This segment is forecasted to grow at a 33 per cent CAGR, reaching ₹140 crore in revenue by FY27. Pediatric dental products: Motilal Oswal projects this niche segment to grow a 31 per cent CAGR, reaching ₹44.9 crore by FY27. As Laxmi Dental is India's only manufacturer of US FDA-cleared Silver Diamine Fluoride (SDF) and developer of the patented Bioflx zirconia crowns, the company is expected to benefit from the segment growth. Laxmi Dental listing The stock listed on bourses on January 20, 2025. On the National Stock Exchange (NSE), Laxmi Dental IPO listing price was ₹542 per share, reflecting a listing gain of 26.6 per cent or ₹114, as against the issue price of ₹428. Similarly, on the BSE, Laxmi Dental shares listed at ₹528 apiece, commanding a premium of 23.3 per cent or ₹100, as compared to its initial public offering (IPO) issue price.
Business Standard
3 days ago
- Business Standard
Indegene launches NEXT Medical Writing Automation
Indegene has announced the launch of NEXT Medical Writing Automation to accelerate the creation of high-quality documents across clinical development, regulatory submissions, and beyond. NEXT Medical Writing Automation, an advanced platform that combines deep medical writing expertise with generative AI (GenAI). Purpose-built by experienced medical writers, NEXT Medical Writing Automation operates within familiar environments like Microsoft Word, auto-generating compliant drafts that adapt to diverse sponsor formats and workflows. It integrates seamlessly with Regulatory Information Management (RIM) systems, maintaining traceability and consistency across documents. NEXT Medical Writing Automation combines Indegenes decades of domain knowledge with the power of its AI engine, Cortex. Sameer Lal, SVP, Enterprise Medical Solutions, Indegene, said, With automated scheduling, intelligent task assignments, and robust data flow integration, NEXT Medical Writing Automation helps life sciences organizations scale operations efficiently while maintaining a strong compliance backbone. As document requirements grow and scrutiny intensifies, such solutions become essential to sustaining operational excellence. We see this platform as more than automationits about elevating the entire practice of medical writing. Writers can now focus on strategic tasks and critical thinking, while the platform manages the heavy lift of data and formatting. Indegene is a digital-first life sciences commercialization company that partners with biopharmaceutical, emerging biotech, and medical device companies to develop products, bring them to market, and enhance their impact throughout the product lifecyclemore effectively, efficiently, and in a modern, technology-driven manner. The companys consolidated net profit jumped 24.1% to Rs 117.60 crore on 12.3% increase in net sales to Rs 755.60 crore in Q4 FY25 over Q4 FY24. The scrip declined 1.02% to settle at Rs 564.35 on the BSE.
New Indian Express
6 days ago
- New Indian Express
Transporters slam discriminatory ban on diesel buses registered outside Delhi
Operators say many of these BS-IV diesel vehicles, purchased in 2020, are still in near-new condition because they remained idle for extended periods during the COVID-19 lockdowns. They added that the financial burden during that time was immense. 'Bankers and private financiers took away many of our buses due to EMI defaults. Some operators managed to retain their vehicles by taking loans from private lenders or even selling family gold. The government provided no relief to bus owners during this crisis,' said Sanjay Samrat, President of the Delhi Taxi and Tourist Transporters Association. Transporters argue that the CAQM's decision to phase out BS-IV vehicles after only five to six years of service violates the very norms set by the Supreme Court and the National Green Tribunal, which mandate a 10-year operational life for diesel vehicles in the Delhi-NCR region. 'Our vehicles have valid registration certificates that allow them to operate for 10 years. If this is the legal lifespan, why is the CAQM banning them prematurely? This isn't just about buses—it's about the drivers, cleaners, helpers, and entire families whose livelihoods depend on these vehicles,' said the association in a letter to Delhi Environment Minister Manjinder Singh Sirsa. The transporters have appealed to the minister to intervene and push for a revision of the order, urging that BS-IV diesel buses be allowed to operate until the end of their valid registration period. They say a sudden ban will not only cripple their businesses but also render crores worth of investment worthless.
